Esaxerenone is a new nonsteroidal MR blocker that has been approved in Japan for the treatment of hypertension and is now under development by Daiichi Sankyo Co., Ltd. for diabetic nephropathy [8]. The gene discussed is NR3C2; the disease is hypertensive disorder.